Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab after CAR-T failure in CD19+ lymphomas
NCT02650999Phase 2Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2016
- Primary completion
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL), sponsored by Abramson Cancer Center. Primary endpoint: Dose-limiting Toxicity at 3 years. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02650999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650999.